Lumen Bioscience Announces Appointment of Marcos Milla, Ph.D. to Board of Directors & Expansion of Leadership Team

by admin | Apr 21, 2021 | Press Release

Seattle, WA, April 22, 2020 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Marcos Milla, Ph.D., to the company’s board of directors and the expansion of its...

Developing a biologic to prevent gastrointestinal diseases

by admin | Mar 30, 2021 | Press Release

Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

by admin | Mar 18, 2021 | Press Release

Beyond the lung: treating the GI symptoms of Covid-19

by admin | Feb 16, 2021 | Press Release

CARB-X awards $5.3M to Lumen for diarrheal disease research, development

by admin | Feb 12, 2021 | Press Release

Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform

by admin | Feb 12, 2021 | Press Release